About Imvax
Imvax is a company based in Philadelphia (United States) founded in 2015 by David Andrews. Imvax has raised $203.83 million across 5 funding rounds from investors including Magnetar Capital, Invus and TLP Investments. The company has 50 employees. Imvax offers products and services including IGV-001, Goldspire Platform, IHC-001, and IUC-001. Imvax operates in a competitive market with competitors including GT Medical Technologies, Basilea, BriaCell Therapeutics, Laminar Pharma and SOM Biotech, among others.
- Total Equity Funding$203.83M (USD)
in 5 rounds
- Latest Funding Round$29M (USD), Series C
Jan 2025
- InvestorsMagnetar Capital
& 4 more
- Employee Count50
Products & Services of Imvax
Imvax offers a comprehensive portfolio of products and services, including IGV-001, Goldspire Platform, IHC-001, and IUC-001.
Treats newly diagnosed glioblastoma through clinical trials
Captures tumor antigens for personalized cancer treatments
Preclinical treatment for solid tumors
Targets various solid tumor applications
Funding Insights of Imvax
Imvax has successfully raised a total of $203.83M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $29 million completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $203.83M
- Total Rounds 5
- Last Round Series C — $29M
- First Round $14.69M
(Jun 2017)
- Investors Count 5
All 5 funding rounds of Imvax with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2025 | $29M | Series C | – | – | – |
| Sep 2023 | $23M | Series C | – | – | – |
| Jul 2020 | $112.37M | Series C | – | HP Wild Holding | |
| May 2019 | $24.76M | Series B | – | – | – |
| Jun 2017 | $14.69M | Series A | – | – | – |
5 investors in total: 5 institutional.
Investors in Imvax
Imvax has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Magnetar Capital, Invus and TLP Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Magnetar Capital is engaged in alternative asset management. | – | magnetar.com | Evanston, United States | |
Long-term private equity investments in transformational opportunities are pursued. | – | invus.com | New York, United States | |
- | – | hpwildholding.tcc.mode | - | |
- | – | ziffcapitalpartners.tcc.mode | - | |
Capital is invested by TLP Investments for economic and social impact. | – | tlpinvest.com | Libertyville, United States |
Investor details for Imvax
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Imvax
21 people are tracked at Imvax (11 in leadership, 10 in board & advisors); the tracked headcount is 50.
| Name | Role | Group |
|---|---|---|
David Andrews | Co-Founder & Chief Medical Officer | Leadership |
Sean Hemingway | COO | Leadership |
John M. Limongelli | Chief Legal Officer | Leadership |
John P. Furey | CEO | Leadership |
David W. Andrews | Co-Founder & Chief Medical Officer | Leadership |
Diana Martine | Head, Human Resources | Leadership |
Josh Muntner | CFO | Leadership |
Danielle Kadingo Thompson | Vice President, Finance | Leadership |
Jeff Geibel | Head Of Information Technology | Leadership |
Anthony Zuccarello, MBA, PMP, CSM | Head of Supply Chain, Logistics, Procurement & Planning | Leadership |
Raul Perez-Olle | SVP, Head of Medical Affairs and Late-Stage Clinical Development | Leadership |
Ted Koutouzis | Director | Board & advisors |
Ira Brind | Director | Board & advisors |
Shefali Agarwal | Scientific Advisor | Board & advisors |
David G. Bunning | Director | Board & advisors |
Peter B. Corr | Co-Founder & Chairman | Board & advisors |
Steven M. Altschuler | Director | Board & advisors |
Wendy Dicicco | Director | Board & advisors |
Tyler Curiel | Scientific Advisor | Board & advisors |
Thomas Pfisterer | Director | Board & advisors |
1 more people are available in the full profile.
Complete people profiles for Imvax
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Imvax
3 dated milestones of Imvax across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Imvax is founded.
- Funding First funding round of $14.7M.
- Funding Latest funding round, Series C, of $29.0M.
Competitors of Imvax
Imvax operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GT Medical Technologies, Basilea, BriaCell Therapeutics, Laminar Pharma and SOM Biotech, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| gtmedtech.com | 2017 | Tempe, United States | $129.94M | 29 | Medical devices for brain tumor radiation therapy are provided. | |
| basilea.com | 1999 | Basel, Switzerland | – | – | Antibiotics, antifungals, and oncology drugs are developed for disease treatment. | |
| briacell.com | 2004 | Beverly Hills, United States | – | 16 | Developer of immunotherapies for the treatment of cancer | |
| laminarpharma.com | 2006 | Palma, Spain | $14.71M | – | Melipathy-based drugs are developed for cancer, Alzheimer's, and inflammation treatments. | |
| sombiotech.com | 2009 | Barcelona, Spain | $28.52M | – | Developer of platform for screening compounds to treat rare diseases | |
| brenus-pharma.com | 2020 | Issoire, France | $25M | – | Immunotherapy for cancer treatment is developed by Brenus Pharma. | |
| cellgenesys.com | 1988 | Hayward, United States | $310,000 | – | Cell-based immunotherapies and oncolytic virus therapies for cancer are developed. |
Detailed competitors of Imvax
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Imvax
The website of Imvax (imvax.com) receives about 3K visits a month.
- Monthly visits3K
▼ 15.3% vs previous month
Latest news on Imvax
Complete news archive for Imvax
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Imvax
10 companies that operate in the same segment as Imvax (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Imvax
Imvax was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Imvax is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Imvax is a funded company, having raised a total of $203.83M across 5 funding rounds to date. The company's 1st funding round was a Series A of $14.69M, raised on Jun 2017.
Imvax has 50 employees.
Imvax was founded in 2015 and is headquartered in Philadelphia, United States. Patient-specific vaccines and immunotherapies targeting malignant gliomas and other cancers are developed by the company within the biotechnology sector. The lead product, IGV-001, an autologous tumor cell vaccine designed to activate immune responses against cancer cells, is undergoing phase 1 clinical trials.
Imvax's top competitors include GT Medical Technologies, BriaCell Therapeutics and Basilea.
Imvax offers IGV-001, Goldspire Platform, IHC-001, and IUC-001.
Imvax has 5 investors. Key investors include Magnetar Capital, Invus, TLP Investments, HP Wild Holding, and Ziff Capital Partners.
Imvax operates through Imvax, Inc..